High-risk neuroblastoma has historically been and continues to be an immensely difficult disease to treat in the pediatric population. It is important to identify its pathophysiology and molecular pathology to understand the role of immunotherapy, the barriers encountered with immunotherapy, and the potential for promising breakthroughs in high-risk neuroblastoma.